State Key Laboratory of Agricultural Microbiology, Huazhong Agricultural Universitygrid.35155.37, Wuhan, China.
Key Laboratory of Preventive Veterinary Medicine of Hubei Province, Huazhong Agricultural Universitygrid.35155.37, Wuhan, China.
J Virol. 2021 Nov 9;95(23):e0141421. doi: 10.1128/JVI.01414-21. Epub 2021 Sep 8.
Rabies, caused by rabies virus (RABV), remains a serious threat to public health in most countries worldwide. At present, the administration of rabies vaccines has been the most effective strategy to control rabies. Herein, we evaluate the effect of colloidal manganese salt (Mn jelly [MnJ]) as an adjuvant of rabies vaccine in mice, cats, and dogs. The results showed that MnJ promoted type I interferon (IFN-I) and cytokine production and the maturation of dendritic cells (DCs) and . Besides, MnJ serving as an adjuvant for rabies vaccines could significantly facilitate the generation of T follicular helper (Tfh) cells, germinal center (GC) B cells, plasma cells (PCs), and RABV-specific antibody-secreting cells (ASCs), consequently improve the immunogenicity of rabies vaccines, and provide better protection against virulent RABV challenge. Similarly, MnJ enhanced the humoral immune response in cats and dogs as well. Collectively, our results suggest that MnJ can facilitate the maturation of DCs during rabies vaccination, which can be a promising adjuvant candidate for rabies vaccines. Extending the humoral immune response by using adjuvants is an important strategy for vaccine development. In this study, a novel adjuvant, MnJ, supplemented in rabies vaccines was evaluated in mice, cats, and dogs. Our results in the mouse model revealed that MnJ increased the numbers of mature DCs, Tfh cells, GC B cells, PCs, and RABV-specific ASCs, resulting in enhanced immunogenicity and protection rate of rabies vaccines. We further found that MnJ had the same stimulative effect in cats and dogs. Our study provides the first evidence that MnJ serving as a novel adjuvant of rabies vaccines can boost the immune response in both a mouse and pet model.
狂犬病由狂犬病病毒（RABV）引起，在世界大多数国家仍然是对公众健康的严重威胁。目前，狂犬病疫苗的管理是控制狂犬病最有效的策略。在此，我们评估胶体锰盐（Mn 胶[MnJ]）作为狂犬病疫苗在小鼠、猫和狗中的佐剂的效果。结果表明，MnJ 促进了 I 型干扰素（IFN-I）和细胞因子的产生[1,2]，以及树突状细胞（DC）的成熟[3]。此外，MnJ 作为狂犬病疫苗的佐剂可以显著促进滤泡辅助性 T 细胞（Tfh）细胞、生发中心（GC）B 细胞、浆细胞（PC）和狂犬病特异性抗体分泌细胞（ASC）的产生，从而提高狂犬病疫苗的免疫原性，并提供更好的针对强毒 RABV 攻击的保护[1,4]。同样，MnJ 也增强了猫和狗的体液免疫反应[5,6]。总之，我们的研究结果表明，MnJ 可以促进狂犬病疫苗接种期间 DC 的成熟，是狂犬病疫苗的一种有前途的佐剂候选物。通过使用佐剂来扩展体液免疫反应是疫苗开发的重要策略。在这项研究中，评估了新型佐剂 MnJ 对狂犬病疫苗在小鼠、猫和狗中的作用。我们在小鼠模型中的结果表明，MnJ 增加了成熟 DC、Tfh 细胞、GC B 细胞、PC 和狂犬病特异性 ASC 的数量，从而提高了狂犬病疫苗的免疫原性和保护率。我们进一步发现 MnJ 在猫和狗中也具有相同的刺激作用。我们的研究首次提供了证据，表明 MnJ 作为狂犬病疫苗的新型佐剂，可以在小鼠和宠物模型中增强免疫反应。
